IGF-1 DES
IGF-1 DES is a truncated form of IGF-1 with significantly higher potency and a short half-life, profiled for localized muscle growth and hypertrophy. Captured community reports are essentially nonexistent, and the only available human-use guidance is a sparse clinician reference recommending 75 mcg injected intramuscularly each day, typically cycled rather than maintained continuously. The peptide carries no FDA-approved indication; all human use is off-label or compounded, resting entirely on preclinical animal studies with no human trial data behind it.
Research Evidence
Evidence shape
No completed human trials extracted for IGF-1 DES. Animal-model evidence carries the indication cards below.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How IGF-1 DES is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
- Frequency
- daily
- Timing
- unspecified
- Route
- IM
- Cycle
- unspecified
Clinician protocols dose 75 µg daily IM (1 source).
No structured protocol details captured for this tier yet.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for IGF-1 DES, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.